The CCL20 and CCR6 axis in psoriasis

Scand J Immunol. 2020 Mar;91(3):e12846. doi: 10.1111/sji.12846. Epub 2019 Nov 24.

Abstract

Psoriasis is a TNF-α/IL-23/IL-17A-mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL-17A-producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL-17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL-17A-rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.

Keywords: CCL20; CCR6; Koebner phenomenon; Th17; psoriasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers
  • Chemokine CCL20 / genetics
  • Chemokine CCL20 / metabolism*
  • Disease Susceptibility*
  • Gene Expression Regulation / drug effects
  • Humans
  • Molecular Targeted Therapy
  • Psoriasis / diagnosis
  • Psoriasis / etiology*
  • Psoriasis / metabolism*
  • Psoriasis / therapy
  • Receptors, CCR6 / genetics
  • Receptors, CCR6 / metabolism*
  • Signal Transduction / drug effects

Substances

  • Biomarkers
  • CCL20 protein, human
  • CCR6 protein, human
  • Chemokine CCL20
  • Receptors, CCR6